Other Mutations: NTRK

NCT05225259: Expanded Access for LOXO-260 in Participants With Cancer Caused by an Abnormal RET Gene That Did Not Respond/is no Longer Responding to Treatment With a Type of Drug Called a RET Inhibitor

NCT05225259
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: NTRK, RET
Breast Cancer Tissue: 
Recruitment Status: Available

Drug Category: Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 12 Years and older (Child, Adult, Older Adult))
Location of Metastases: 
Additional Notes: Patients must be medically suitable for treatment with LOXO-260, but not eligible or able to participate in an ongoing LOXO-260 clinical trial
Exclusions: 
https://ClinicalTrials.gov/show/NCT05225259

NCT05004116: A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer

NCT05004116
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: ALK, ROS, NTRK
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Tyrosine-Kinase Inhibitor, Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 1 Year to 25 Years (Child, Adult)
Location of Metastases: 
Additional Notes: Patients are not required to have tumors that express ALK, ROS, NTRK mutations
Exclusions: Patients over the age of 25; Patients with unstable or untreated central nervous system (brain or leptomeningeal) metastases that require steroids- see trial for details
https://ClinicalTrials.gov/show/NCT05004116

Up ↑